Table 1 Patient Characteristics.
All Patients | Refractory (DR) | Intolerant (INT) | |
|---|---|---|---|
n = 173 | n = 127 | n = 46 | |
Age at Diagnosis, median (range) | 34 (16–89) | 33 (16-89) | 40 (18-87) |
Sex, n (%) | |||
Male | 105 (60.7) | 76 (59.8) | 29 (63.0) |
Female | 68 (39.3) | 51 (40.2) | 17 (37.0) |
Race, n (%) | |||
Caucasian | 136 (78.6) | 100 (78.7) | 36 (78.3) |
African American | 25 (14.5) | 18 (14.2) | 7 (15.2) |
Hispanic | 6 (3.5) | 5 (3.9) | 1 (2.2) |
Other | 6 (3.5) | 5 (3.2) | 2 (4.4) |
cHL Subtype | |||
Nodular Sclerosing | 118 (68.2) | 86 (67.7) | 32 (69.6) |
Mixed Cellularity | 18 (10.4) | 10 (7.9) | 8 (17.4) |
Lymphocyte Rich | 1 (0.6) | 1 (0.8) | 0 (0) |
Lymphocyte Deplete | 6 (3.5) | 6 (4.7) | 0 (0) |
Unknown | 30 (17.3) | 24 (18.9) | 6 (13.0) |
Stage At Diagnosis | |||
Limited (I-II) | 36 (20.8) | 29 (22.8) | 7 (15.2) |
Advanced (III-IV) | 132 (76.3) | 97 (76.4) | 35 (76.1) |
Unknown | 5 (2.9) | 1 (0.8) | 4 (8.7) |
Front-line Therapy | |||
ABVD/AVD | 134 (77.5) | 96 (75.6) | 38 (82.6) |
BV-AVD | 15 (8.7) | 12 (9.5) | 3 (6.5) |
BV + Nivo | 5 (2.9) | 5 (3.9) | 0 (0) |
BV +/- Chemo | 10 (5.8) | 7 (5.5) | 3 (6.5) |
Other | 9 (5.2) | 7 (5.5) | 2 (4.4) |
Front-line CR | |||
Yes | 63 (36.4) | 44 (34.7) | 19 (41.3) |
No | 105 (60.7) | 81 (63.8) | 24 (52.2) |
Unknown | 5 (2.9) | 2 (1.6) | 3 (6.5) |
Front-line Refractory | |||
Yes | 100 (57.8) | 77 (60.6) | 23 (50.0) |
No | 71 (41.0) | 49 (38.6) | 22 (47.8) |
Unknown | 2 (1.2) | 1 (0.8) | 1 (2.2) |
